At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
MC2-25 cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Parallel Group (2-arm), Randomised, Double-blind, 12-week Trial to Explore the Efficacy and Safety of MC2-25 Cream and MC2-25 Vehicle in Women Diagnosed With Vulvar Lichen Sclerosus (VLS)
In Brief
A Phase 2 clinical trial evaluating MC2-25 cream and MC2-25 vehicle for Vulvar Lichen Sclerosus. Completed, enrolled 33 participants across 1 site.
Detailed Summary
The purpose of this study is to explore the efficacy and safety of MC2-25 cream and MC2-25 vehicle in women with vulvar lichen schelosus (VLS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVulvar Lichen Sclerosus
CountriesDenmark
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
Enrollment StartOct 2023
First PostedNov 2023
Primary CompletionNov 2024
TodayJul 2026
First PostedNov 15, 2023
Enrollment StartOct 11, 2023
Primary CompletionNov 8, 2024
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 2.6 years ago
Interventions
MC2-25 creamdrug
Topical application
MC2-25 vehicledrug
Topical application